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Human α-galactosidase A (GLA) has been used in enzyme 
replacement therapy for patients with Fabry disease. We 
expressed recombinant GLA from Chinese hamster ovary cells 
with very high productivity. When compared to an approved 
GLA (agalsidase beta), its size and charge were found to be 
smaller and more neutral. These differences resulted from the 
lack of terminal sialic acids playing essential roles in the serum 
half-life and proper tissue targeting. Because a simple 
sialylation reaction was not enough to increase the sialic acid 
content, a combined reaction using galactosyltransferase, 
sialyltransferase, and their sugar substrates at the same time 
was developed and optimized to reduce the incubation time. 
The product generated by this reaction had nearly the same 
size, isoelectric points, and sialic acid content as agalsidase 
beta. Furthermore, it had better in vivo efficacy to degrade the 
accumulated globotriaosylceramide in target organs of Fabry 
mice compared to an unmodified version. [BMB Reports 2013; 
46(3): 157-162]
INTRODUCTION
Fabry disease, an X-linked genetic disease, is known to arise 
from a deficiency in the lysosomal enzyme α-galactosidase A 
(GLA), which hydrolyzes the terminal α-galactosyl moieties 
from glycolipids and glycoproteins. Defects in the encoding 
gene cause a failure to catabolize alpha-D-galactosyl glyco-
lipid moieties in the lysosome. The resulting accumulation of 
globotriaosylceramide (Gb3) leads to progressive multi-sys-
temic damage to the kidney, heart, and cerebrovascular 
system. Early symptoms of this form of glycolipid accumu-
lation include peripheral extremities, vascular skin lesions, de-
creased sweating and corneal opacity. With increasing age, 
these symptoms develop into functional failures in the heart, 
brain, and kidney, finally leading to death.
　Several lysosomal storage diseases, including Fabry disease, 
can be treated with enzyme replacement therapy by employ-
ing an injection of a recombinant enzyme with proper glycans 
for lysosomal targeting. Currently, two different recombinant 
GLAs are developed and approved as therapeutic enzymes for 
Fabry disease. One is agalsidase beta (Fabrazyme, Genzyme) 
produced in CHO cells and the other agalsidase alfa (Replagal, 
Shire HGT) generated in human cultured fibroblasts. Compara-
tive studies of their glycosylation patterns, enzyme activities 
and therapeutic effects have been reported (1, 2). Both en-
zymes are homodimeric glycoproteins with the same amino 
acid sequences having three N-glycosylation sites in each 
monomer. However, the differences in the glycosylation pat-
terns between two products are observed mainly in the con-
tents of sialic acid and mannose-6-phosphate (1, 2). These two 
sugar residues are essential factors for the successful targeting 
to the lysosomes of the tissues affected in Fabry patients. 
Specifically, the mannose-6-phosphate residues of lysosomal 
enzymes are recognized by mannose-6-phosphate receptors 
and the enzymes are transported to the lysosome via the 
endosome. However, some portions escaping this pathway are 
secreted into the extracellular space and can be retaken up by 
mannose-6-phosphate receptors located on the plasma 
membrane. This “secretion recapture” mechanism utilizing 
mannose-6-phosphate receptors has been the basis for func-
tional complementation by an injection of recombinant enzy-
mes. Successful targeting also requires the terminal sialic acid 
capping of complex type glycans, as the asialoglycoprotein re-
ceptor in the liver rapidly removes the glycoprotein containing 
the exposed galactose residues from blood circulation. The in-
creased level of sialic acids of glycoproteins is well known to 
correlate with the prolonged half-life in the serum (3). Studies 
comparing both GLA products reported that agalsidase beta 
showed superior activity in Fabry mouse models, mainly due 
to the fact that it contains higher contents of mannose-6-phos-
phate and sialic acid (1, 2). 
　We expressed GLA in CHO cells using conventional re-
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aThe ratios between sialic acid and galactose were calculated in order to estimate the level of sialic acid capping. 
Table 1. Monosaccharide compositions of recombinant GLAs
Fig. 1. Comparison of the sizes and 
charges of agalsidase beta and I303. 
(A) Sizes of agalsidase beta (Fbz; Fab-
razyme) and I303 were compared in 
SDS-PAGE before and after deglycosy-
lation using PNGase F digestion. Here, 
M represents the molecular weight mar-
ker. (B) Their isoelectric patterns were 
analyzed in IEF gel with/without a 
sialidase treatment. Here, I303-1 and 
I303-2 represent two different batches 
of the I303 product.
combinant technologies with much higher productivity com-
pared to that of agalsidase beta. Unfortunately, the produced 
recombinant GLA was found to have a low level of sialic acid, 
which may have been caused by the biased selection of a high 
producer lacking the capability to add sialic acids. To enhance 
its sialic acid content, an in vitro glycosylation reaction using 
galactosyltransferase, sialyltransferase and their sugar sub-
strates was established and optimized. The sialic acid content 
and in vivo efficacy of the resulting glycosylated product were 
analyzed in a parallel comparison with agalsidase beta and un-
modified GLA. 
RESULTS AND DISCUSSION
GLA produced from high-producer CHO cells lacks sialic 
acid contents
The gene encoding GLA was amplified from the cDNA of hu-
man fibroblast by a polymerase chain reaction and cloned into 
the CHO cell expression vector containing the dihydrofolate re-
ductase (DHFR) gene. The resulting vector was transfected to a 
DHFR-deficient CHO cell line (DG44) after which high-ex-
pressing clones were generated by a conventional methotrexate 
(MTX) amplification method. The productivity of the selected 
clone was measured as more than 150 mg/L/day by an en-
zyme-linked immunosorbent assay (data not shown), which is 
>30 times higher than the productivity (5 mg/L/day) in the hol-
low fiber bioreactor described in the patent for agalsidase beta 
(EP2210947). Recombinant GLA was purified from the cell cul-
ture supernatant by three purification steps including anion ex-
change and hydrophobic interaction chromatography resins, 
and the purity after each step was checked by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Supple-
mentary Fig S1A). Interestingly, weak intensity of the GLA ho-
modimer band was detected around ∼95 kDa, even in the de-
naturing condition of SDS-PAGE, while a strong monomer 
band was noted between 42 and 49 kDa. In contrast, the peak 
of the GLA homodimer was only detected in gel permeation 
chromatography with more than 99% purity (Supplementary 
Fig. S1C). It was termed I303.
　The size of I303 was found slightly smaller than that of agal-
sidase beta when compared in SDS-PAGE (Fig. 1A). However, 
after deglycosylation using peptide N-glycosidase (PNGase) F, 
both enzymes showed nearly identical mobility levels, indicat-
ing that the relatively smaller size of I303 resulted from the dif-
ferent N-linked glycosylation. Furthermore, an image of the 
isoelectric focusing (IEF) gel showed that the multiple bands of 
I303 are located in more neutral areas, in contrast to those of 
agalsidase beta, which are dispersed in acidic regions (Fig. 
1B). Here, two different batches of I303 were compared, and 
both of them found in more neutral regions although slight 
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Fig. 2. Changes of charge and size in-
duced by enhanced sialylation. (A) 
After in vitro glycosylation including 2x 
sialylation (2x Sial) and 2x combined 
(2x Comb) reactions, isoelectric points 
of I303 were moved to more acidic re-
gions, which are comparable to those 
of agalsidase beta (Fbz; Fabrazyme). (B) 
The size of the I303ES generated by 
the 2x combined reaction increased 
slightly to have the same mobility as 
agalsidase beta in SDS-PAGE. (C) 
Changes in the size and charge in-
duced by the 2x combined reaction 
were analyzed in 2D gel. 
batch variations were observed. After the removal of sialic 
acids by a sialidase treatment, these different patterns of iso-
forms were converged to the same pattern of multiple bands 
with a neutral shift, which confirmed that the differences in the 
isoelectric patterns were caused by negative charges of sialic 
acids. Notably, although the complexities of multiple bands 
were greatly reduced after the sialidase treatment, multiple pat-
terns representing charge heterogeneity still existed, suggesting 
that there are other factors, such as mannose-6-phosphate, 
contributing to the complex charge status. 
　Direct analysis of the monosaccharide composition showed 
that one mole of I303 had only 2.8 mol of sialic acids, which 
was less than half of the sialic acid content of agalsidase beta 
(7.3 mol/mol protein, Table 1). From the ratio of the sialic acid 
and galactose amounts, it could be calculated that only ∼65% 
of all galactosyl residues are capped with terminal sialic acids, 
in contrast to ~88% for agalsidase beta (Table 1). Taken to-
gether, I303, having an equivalent protein moiety with agalsi-
dase beta, appears to experience incomplete sialylation possi-
bly due to the gap between the high level of protein pro-
duction and the low capacity of the glycosylation process tak-
ing place during secretion. 
Establishment of an in vitro enzyme reaction to enhance 
sialylation
To increase the sialic acid content of I303, we initially carried 
out an in vitro enzyme reaction using α(2,3)-sialyltransferase 
and CMP-N-acetylneuraminic acid (NANA) as the donor sugar 
based on a previously reported reaction condition (4). Here, 
NANA is the most commonly found sialic acids. However, this 
simple reaction scarcely affected the charge status of I303, in-
dicating an insignificant increase in sialylation (Supplementary 
Fig. S2A). To avoid cases in which the activity of sialyltransfer-
ase is reduced and/or the donor sugar becomes exhausted dur-
ing a long incubation time, another aliquot of sialyltransferase 
and CMP-NANA was added after 12 hours of incubation, 
which was then followed by further incubation for 12 hours. 
However, the resulting sialylation increase was still insigni-
ficant. Therefore, it was postulated that an efficient increase in 
sialylation also requires the addition of galactose to the ex-
posed terminal N-acetylglucosamines of the glycans as a pre-
requisite reaction.
　Galactosylation was combined with sialylation with two dif-
ferent ways in an effort to find the best condition. First, in a 
stepwise reaction, galactosylation using β(1,4)-galactosyl-
transferase and UDP-galactose as the donor sugar was carried 
out and then followed by sialylation as described in the pre-
vious paragraph. On the other hand, the combined reaction 
represents a single-step reaction in which I303 was treated 
with a combination of α(2,3)-sialyltransferase and β(1,4)-ga-
lactosyltransferase in the presence of CMP-NANA and 
UDP-galactose as the donor sugars. The conditions for both re-
actions are described in the Materials and Methods section 
and are summarized in Supplementary Table S1. Both re-
actions added more sialic acids to I303 than simple sialylation 
(Supplementary Fig. S2), which confirmed the prerequisite of 
galactosylation for efficient sialylation. However, the sialyla-
tion levels of the resulting products were still lower when 
compared to that of agalsidase beta. As a subsequent attempt, 
we increased the amount of glycosyltransferases and donor 
sugars by two times compared to those previously reported (4). 
This doubling in a combined reaction condition (2x combined) 
dramatically increased the sialic acid content of I303 
(Supplementary Fig. S2A). Finally, we tested whether the in-
cubation time of this reaction could be shortened because the 
prolonged reaction at 37oC may have harmful effects on the 
enzyme activity and stability of GLA. As a combined reaction 
has the advantage of reducing the incubation time compared 
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Fig. 3. Effects of agalsidase beta, I303, and I303ES in Fabry mice. 
(A) The GLA activities in the liver, kidney and spleen were 
measured. Fabry mice were sacrificed 72 hours after the sin-
gle-dose injection (1 mg/kg body weight) of GLAs. (B) Levels of 
Gb3 in the same organs were analyzed 72 hours after the 
injection. Wild-type mice, open bar; Fabry mice, filled bar; Fabry 
mice injected with agalsidase beta, dotted bar; Fabry mice in-
jected with I303, vertically striped bar; Fabry mice injected with 
I303ES, hatched bar. Error bars represent the mean ± standard de-
viation (n = 3). 
to a stepwise reaction, only 2x combined reactions with differ-
ent incubation times were analyzed. Surprisingly, an enhance-
ment of the sialylation process was almost completely ach-
ieved in only 2 hours and reached a plateau (Supplementary 
Fig. S2B). We selected a 6-hour incubation time for the 2x 
combined reaction as a sufficient time without batch 
variations. The I303 containing an enhanced amount of sialic 
acid by this reaction was renamed as I303ES. 
Comparison of I303ES with I303 and agalsidase beta
The charge and size of I303ES generated by the 2x combined 
reaction were compared with those of agalsidase beta and 
I303 by IEF, SDS-PAGE and 2D-gel analysis (Fig. 2). The charg-
ed status of I303 was shifted to a similar acidic region of agal-
sidase beta only by the 2x combined reaction (Fig. 2A). The in-
complete increase in the sialic acid content by 2x sialylation 
without galactosylation clearly showed the requirement of the 
galactosylation as a prerequisite again. The size of I303ES was 
larger than that of I303, which is nearly the same size as agal-
sidase beta (Fig. 2B). Interestingly, a doublet-containing weak 
band of a smaller size was observed in agalsidase beta, where-
as the I303ES displayed a single protein band corresponding to 
the upper band of the doublet. Also, the charge and size of 
three GLAs were compared at the same time through a 2D-gel 
analysis (Fig. 2C). The bands of I303ES were detected in nearly 
the same region of the agalsidase beta bands, while I303 
bands were located in a more neutral and smaller area. 
Notably, I303ES showed a more continuous band pattern while 
agalsidase beta and I303 had discrete band patterns, especially 
in the first IEF dimension. 
　Monosaccharide compositions of agalsidase beta, I303 and 
I303ES were determined by high-pH anion exchange chroma-
tography (Table 1). One mol of I303ES was shown to have 
∼6.2 mol of sialic acid and ∼5.7 mol of galactose, which 
were 220% and 130% increases, respectively, as compared to 
∼2.8 mol of sialic acid and ∼4.3 mol of galactose in I303. 
These values were slightly lower than the ∼7.3 mol of sialic 
acid and 8.3 mol of galactose for agalsidase beta. However, it 
is noteworthy that I303ES showed a higher ratio of sialic acid to 
galactose than agalsidase beta (Table 1). The calculated ratio of 
1.09, which was more than one, represented complete sialic 
acid capping without exposed galactose residue. Here, the val-
ue over one can be explained as resulting from experimental 
errors when considering the high values of the standard 
deviations. All GLAs showed high levels of mannose with ＞14 
mol per mol of protein, which represented the presence of 
high-mannose-type glycans considering three N-glycosylation 
sites of GLA. Also, they had similar levels of man-
nose-6-phosphate (2.9-3.2 mol per mol protein) which is one of 
the major factors determining the proper lysosomal targeting. 
In vivo efficacies of recombinant GLAs compared in Fabry 
mice
We employed Fabry mice (GLA gene knock-out) for in vivo ef-
ficacy analyses of agalsidase beta, I303, and I303ES. The en-
zyme activities of GLA in the liver, kidney and spleen were an-
alyzed 72 hours after an injection into the tail vein of Fabry 
mice (Fig. 3A). As expected, the GLA activities in the kidney 
and spleen of the Fabry mice were strikingly lower than those 
of the wild type. The injections of all three recombinant GLAs 
into Fabry mice greatly increased these activities up to a level 
far over those of the wild type, but the degrees of the increases 
were different. In this case, I303 and I303ES showed much 
higher activity levels in all of the tested organs compared to 
agalsidase beta, which may result from the differences in the 
enzyme stability levels. Compared to the fresh preparations of 
I303 and I303ES, agalsidase beta may have low stability arising 
from lyophilized storage in the vial, which may be related to 
its doublet band as observed in SDS-PAGE. 
　The instances of degradation of the accumulated Gb3 by the 
injected GLA was also directly analyzed (Fig. 3B). Because 
I303 had glycans with deficient capping of the sialic acids, a 
significant portion of the I303 was expected to be trapped in 
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the liver, containing the asialoglycoprotein receptor, which re-
sults in a short half-life in serum and an unwanted body dis-
tribution pattern. As expected, the Gb3 degradation induced 
by the injection of I303 was lower in the target organs (kidney 
and spleen) as compared to agalsidase beta, while the degra-
dation in the liver was restored up to the level of wild-type 
mice. However, I303ES with increased sialic acid levels via the 
2x combined reaction induced more degradation of Gb3 in 
the kidney and spleen to the level decreased by the injection 
of agalsidase beta. This result clearly represents the im-
portance of sialic acid capping for proper targeting and tissue 
distribution, as the only difference between I303 and I303ES is 
the sialic acid content generated by in vitro glycosylation.    
　For successful enzyme replacement therapy for Fabry dis-
ease, the importance of mannose-6-phosphate and the sialic 
acid content in GLA products has been reported (1,2). 
Mannose-6-phosphate is required to promote the uptake into 
the lysosomes of cells by the mannose-6-phosphate receptor. 
Sialic acid capping is essential to mask terminal galactose, 
which reduces uptake by the asialoglycoprotein receptor in 
the liver and thus results in the proper tissue distributions with 
a long half-life in the body. We succeeded in constructing a 
high-producer cell line with ＞150 mg/L/day productivity. 
Unfortunately, the produced GLA was found to have a low 
level of sialic acid, though it has an amount of man-
nose-6-phosphate similar to that of commercial agalsidase 
beta. Therefore, we developed and optimized an in vitro gly-
cosylation process designed to increase the sialic acid content. 
In particular, a 2x combined reaction using high amounts of 
galactosyltransferase, sialyltransferase, and their sugar sub-
strates at the same time was selected to reduce the incubation 
time which is also a critical factor for enzyme activity and 
stability. The resulting product showed almost complete sialic 
acid capping, which also increased the in vivo efficacy to de-
grade the accumulated Gb3 in the kidney and spleen of Fabry 
mice. This study provides an efficient strategy to enhance the 
sialylation of therapeutic enzymes in vitro and confirms the 
importance of sialic acid capping for proper tissue targeting.   
MATERIALS AND METHODS
Construction of CHO cell lines expressing human GLA
The full-length cDNA of human α-galactosidase was cloned 
from the human fibroblast cDNA library using PCR and the 
cDNA was inserted into the pMSG cloning vector. The ex-
pression vector containing the human α-galactosidase gene 
was transfected into Chinese hamster ovary (CHO) cell lines 
with a DosperTM (Roche) device using the lipo-fectin method. 
After 48 hours of incubation at 37oC with 5% CO2, transfected 
cells were collected and inoculated into 96-well plates at the 
initial cell density (6-7 × 105 cells/well) with fresh α-MEM 
(Gibco, Grand Island, NY, USA) containing 10% dFBS. The 
adapted cell lines were subjected to amplification by increas-
ing the concentration of methotrexate from 10 nM to 1 μM. 
Individual clones were isolated with a limiting dilution meth-
od and clones which expressed the highest levels of GLAs 
were selected after analysis by an enzymatic assay.
Purification of recombinant GLA 
The culture supernatant was centrifuged at 3,000 g for 20 min 
and then further filtered for clarification using a 0.45 μm filter 
(Millipore, Billerica, MA, USA). After a buffer exchange (10 
mM sodium phosphate, pH 7.0), the resulting solution was 
loaded onto a DEAE sepharose fast-flow column (GE 
Healthcare, Uppsala, Sweden) pre-equilibrated with the same 
buffer. Elution was carried out by applying the linear gradient 
(0-0.5 M sodium chloride) of sodium chloride and the fraction 
containing the recombinant GLA was collected. The pooled 
fractions were loaded on hydrophobic interaction chromatog-
raphy (phenyl sepharose high-performance column, GE 
Healthcare) after adjusting their salt concentrations fractions to 
1 M of sodium chloride. The bound recombinant GLA was 
eluted from the column using a linear gradient from 1 to 0 M 
sodium chloride. The fractions containing GLA were collected 
and dialyzed with formulation buffer (50 mM sodium phos-
phate, pH 7.0). The purity and identity were checked by 
SDS-PAGE and Western blotting using the anti-human α-gal-
actosidase monoclonal antibody (ISU ABXIS, Seoul, Korea), 
respectively. 
SDS-PAGE, IEF and 2D-gel analysis
SDS-PAGE was performed using a precast gel in the NuPAGE 
Gel System (Life Technologies, Carlsbad, CA, USA). For the 
determination of the charged status, IEF was performed using 
Novex pH 3-10 IEF Gel (Life technologies). For 2D-gel electro-
phoresis, first-dimension IEF was carried out using a pH 3-10 
immobilized pH gradient (IPG) Immobiline DryStrip on the 
Ettan IPGphor system (GE Healthcare). For the second-di-
mension electrophoresis process, the resulting IPGs strips were 
equilibrated for 15 min by rocking in the first solution (6 M 
urea, 30% glycerol, 2% SDS, bromophenol blue, 1% DTT, 50 
mM Tris-HCl, pH 8.8) and were equilibrated again for 15 min 
in the second solution (6 M urea, 30% glycerol, 2% SDS, bro-
mophenol blue, 2.5% iodoacetamide, 50 mM Tris-HCl, pH 
8.8). The equilibrated strips were laid on 12% SDS-PAGE gel 
with 1% agarose in a cathode buffer and electrophoresis was 
carried out. 
Monosaccharide composition analysis
A monosaccharide analysis for neutral and amino sugars, sialic 
acid and mannose-6-phosphate was carried out using high-per-
formance anion exchange chromatography with pulsed am-
perometric detection (HPAEC-PAD, DX-600, Dionex, Sunny-
vale, CA, USA), as previously described (1) with slight modi-
fications. Briefly, for the analysis of the neutral and amino sug-
ars, 40 μg of samples were hydrolyzed with 2 M of trifluoro-
acetic acid at 100oC for 4 h. The same amounts of samples 
were hydrolyzed under mild acid conditions with either 0.1 M 
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HCl at 80oC for 1 hour or 6.75 M trifluoroacetic acid at 100oC 
for 1.5 hour to release the sialic acid or mannose-6-phosphate, 
respectively. Analytes were separated with CarboPac PA1 or 
PA10 analytical column (Dionex).
Experimental design of in vitro glycosylation
For in vitro glycosylation, the final formulation buffer contain-
ing the active protein ingredient was exchanged for a buffer of 
50 mM of MES at pH 6.4 by repetitive ultracentrifugation using 
an YM-10 Microcon membrane (Millipore). For sialylation, 1 
mg of GLA was incubated in 1 ml of solution in total with 10 
mU recombinant rat α(2,3)-sialyltransferase (Merck, Darms-
tadt, Germany), 5 μmol CMP-NANA and 5 μmol MnCl2 at 
37oC for 12 hours. Then, the same amounts of aliquots of 
α(2,3)-sialyltransferase, CMP-NANA and MnCl2 were added 
and the mixture was further incubated for another 12 hours. 
For stepwise galactosylation and sialylation, 1 mg of GLA was 
also treated with 20 mU bovine β(1,4)-galactosyltransferase 
(Merck), 10 μmol UDP-galactose and 5 μmol MnCl2 at 37oC 
for 12 hours. Then, 20 mU α(2,3)-sialyltransferase, 10 μmol 
CMP-NANA and 5 μmol MnCl2 were added to the reaction 
solution and further incubated for another 12 hours. For com-
bined galactosylation and sialylation, 10 mU β(1,4)-galactosyl-
transferase and 10 mU α(2,3)-sialyltransferase together with 5 
μmol each of UDP-galactose, CMP-NANA and MnCl2 were 
added to the GLA solution (1 mg/ml) and incubated at 37oC 
for 12 hours. Then, another aliquot of galactosyltransferase, 
sialyltransferase, nucleotide sugars and cofactor MnCl2 were 
added and the mixture was incubated for additional 12 hours. 
For 2x sialylation and the 2x combined reaction, doubled 
amounts of glycosyltransferase, nucleotide sugars and a co-
factor were used for the same strategies with the sialylation 
and combined reactions previously described. The amounts of 
reaction components used for all five reactions (sialylation, 
stepwise, combined, 2x sialylation and 2x combined re-
actions) are summarized in Supplementary Table S1. After op-
timization experiments to determine the best reaction con-
dition, the 2x combined reaction with a short reaction time (6 
hours) was selected for the generation of I303ES.
In vivo activity assay using Fabry mice
Fabry mice, which were kindly provided by Dr. Roscoe O. 
Brady of the National Institute of Health (Bethesda, MD, USA), 
were 18 weeks old at the beginning of the study. All mice 
were genotyped by the PCR method, as described previously 
(5). All animals were treated in accordance with the Animal 
Care Guidelines of the Ewha Womans University School of 
Medicine (Seoul, Korea). For enzyme replacement therapy, the 
mice received an infusion of 1.0 mg/kg body weight of agalsi-
dase beta, I303, and I303ES via the tail vein. They were sacri-
ficed 72 hours after the injection and their tissues were 
analyzed. The extraction and saponification of lipids and the 
extraction of the glycolytic fraction were performed as de-
scribed previously (6). The glycolipid fraction was mixed with 
5 ml of N-acetyl-galactosylsphingosine and 795 μl of 80% di-
oxane and then analyzed using a liquid chromatog-
raphy-mass/mass spectrometer system (LC-MS/MS, ABI 4000; 
Applied Biosystems, Foster City, CA, USA). Glycolipid quanti-
tation was performed using a C8 column and an evaporative 
light-scattering detector. The Gb3 standard was obtained from 
Matreya (Pleasant Gap, PA, USA).
Acknowledgements
This study was supported by a grant to D.-B. Oh from the 
Next-Generation BioGreen 21 Program (SSAC-PJ008001).
REFERENCES
1. Lee, K., Jin, X., Zhang, K., Copertino, L., Andrews, L., 
Baker-Malcolm, J., Geagan, L., Qiu, H., Seiger, K., 
Barngrover, D., McPherson, J. M. and Edmunds, T. (2003) 
A biochemical and pharmacological comparison of en-
zyme replacement therapies for the glycolipid storage dis-
order Fabry disease. Glycobiology 13, 305-313.
2. Sakuraba, H., Murata-Ohsawa, M., Kawashima, I., Tajima, 
Y., Kotani, M., Ohshima, T., Chiba, Y., Takashiba, M., 
Jigami, Y., Fukushige, T., Kanzaki, T. and Itoh, K. (2006) 
Comparison of the effects of agalsidase alfa and agalsidase 
beta on cultured human Fabry fibroblasts and Fabry mice. J. 
Hum. Genet. 51, 180-188.
3. Choi, S. S. and Park, T. H. (2006) Enhancement of sialyl-
transferase-catalyzed transfer of sialic acid onto glyco-
protein oligosaccharides using silkworm hemolymph and 
its 30K protein. J. Mol. Catal B: Enz. 43, 128-132.
4. Raju, T. S., Briggs, J. B., Chamow, S. M., Winkler, M. E. 
and Jones, A. J. (2001) Glycoengineering of therapeutic gly-
coproteins: in vitro galactosylation and sialylation of glyco-
proteins with terminal N-acetylglucosamine and galactose 
residues. Biochemistry 40, 8868-8876.
5. Choi, J. O., Lee, M. H., Park, H. Y. and Jung, S. C. (2010) 
Characterization of Fabry mice treated with recombinant 
adeno-associated virus 2/8-mediated gene transfer. J. 
Biomed. Sci. 17, 26.
6. Rose, H. G. and Oklander, M. (1965) Improved procedure 
for the extraction of lipids from human erythrocytes. J. 
Lipid. Res. 6, 428-431.
